New Stock News | Novartis Bio submits application to Hong Kong Stock Exchange

On February 13, Nanjing NoLing Bio-technology Co., Ltd. ("NoLing Bio") submitted an application for listing on the main board of the Hong Kong Stock Exchange, with BOC International as the exclusive sponsor. The prospectus shows that NoLing Bio focuses on the research and commercial application of inhaled nitric oxide (iNO) therapy. With the support of a gas-liquid precision control technology platform, NoLing Bio has established the capability to cover the full chain technology of NO generation, transmission, detection, storage, and clinical application. According to Frost & Sullivan data, NoLing Bio is one of the few companies in the world that can independently control the full chain technology of NO, and is the only company in the world that covers a comprehensive product line for NO therapy and diagnostic applications.